Cargando…

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials

OBJECTIVE: To evaluate gene expression in blood of patients with psoriatic arthritis (PsA) versus healthy controls and identify changes associated with guselkumab treatment. METHODS: Whole blood transcriptome profiling via paired‐end RNA sequencing was conducted using samples from DISCOVER‐1 and DIS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siebert, Stefan, Sweet, Kristen M., Ritchlin, Christopher T., Hsia, Elizabeth C., Kollmeier, Alexa P., Xu, Xie L., Seridi, Loqmane, Song, Qingxuan, Gao, Sheng, Chen, Warner, Miron, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502816/ https://www.ncbi.nlm.nih.gov/pubmed/37553909 http://dx.doi.org/10.1002/acr2.11589

Ejemplares similares

Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
por: Schett, Georg, et al.
Publicado: (2022)

Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
por: Schett, Georg, et al.
Publicado: (2022)

Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
por: Sweet, Kristen, et al.
Publicado: (2021)

Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies
por: McGonagle, Dennis, et al.
Publicado: (2021)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
por: Ritchlin, Christopher T., et al.
Publicado: (2023)

Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study
por: Orbai, Ana-Maria, et al.
Publicado: (2022)

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis
por: Chen, Yang, et al.
Publicado: (2021)

Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study
por: Ritchlin, Christopher T., et al.
Publicado: (2023)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
por: Ritchlin, Christopher T, et al.
Publicado: (2022)

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial
por: Helliwell, Philip S., et al.
Publicado: (2020)

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
por: Mease, Philip J., et al.
Publicado: (2023)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
por: McGonagle, Dennis, et al.
Publicado: (2023)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
por: Kashlan, Reem, et al.
Publicado: (2021)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
por: Rahman, Proton, et al.
Publicado: (2021)

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2021)

Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
por: Schett, Georg, et al.
Publicado: (2023)

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2022)

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2021)

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
por: Ritchlin, Christopher T, et al.
Publicado: (2021)

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2022)

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis
por: Gottlieb, Alice B, et al.
Publicado: (2023)

Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials
por: Kavanaugh, Arthur, et al.
Publicado: (2023)

Guselkumab: widened action in psoriatic disease
por: Arnone, Marcelo, et al.
Publicado: (2021)

Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2022)

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study
por: Mease, Philip J, et al.
Publicado: (2020)

Altered Bone Biology in Psoriatic Arthritis
por: Rahimi, Homaira, et al.
Publicado: (2012)

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
por: Gladman, Dafna D., et al.
Publicado: (2022)

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab
por: Megna, Matteo, et al.
Publicado: (2022)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
por: Orbai, Ana-Maria, et al.
Publicado: (2023)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
por: Siebert, Stefan, et al.
Publicado: (2022)

The evolution of ultraconserved elements with different phylogenetic origins
por: Ryu, Taewoo, et al.
Publicado: (2012)

Dynamic Epigenetic Control of Highly Conserved Noncoding Elements
por: Seridi, Loqmane, et al.
Publicado: (2014)

Arthritis Interception in Patients with Psoriasis Treated with Guselkumab
por: Zabotti, Alen, et al.
Publicado: (2021)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Differences in oxylipin profile in psoriasis versus psoriatic arthritis
por: Coras, Roxana, et al.
Publicado: (2021)

Treatment recommendations for psoriatic arthritis
por: Ritchlin, C T, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_pa2ueonpqrmd3r6ld714arrti9